Protagenic Therapeutics finishes enrollment and dosing for Phase 1 MAD study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Study Completion: Protagenic Therapeutics has completed enrollment and dosing in its Phase 1 study for the lead compound PT00114, which involved healthy volunteers.
Safety Assessment: The study aimed to evaluate the safety and tolerability of PT00114 after multiple doses over time.
Milestone Achievement: With all participants now dosed, the company has reached a significant milestone in the clinical development of its peptide-based therapeutic.
Results Timeline: Protagenic Therapeutics anticipates releasing top-line results from the study by November 30.
Analyst Views on PTIX
About PTIX
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
